Çѱ¹ÁöÁú¤ýµ¿¸Æ°æÈÇÐȸ Á¦11Â÷ International Congress on Lipid & Atherosclerosis (ICoLA 2022) 3ÀÏÂ÷ : 2022-09-17±³À°ÀÏÀÚ : 2022-09-17
±³À°Àå¼Ò : ¿©Àǵµ ÄÜ·¡µå È£ÅÚ
±³À°ÁÖÁ¦ :
Á¦11Â÷ International Congress on Lipid & Atherosclerosis (ICoLA 2022) 3ÀÏÂ÷ÁÖÃÖ±â°ü : Çѱ¹ÁöÁú¤ýµ¿¸Æ°æÈÇÐȸ
´ã´çÀÚ : ICoLA2022 »ç¹«±¹
¿¬¶ôó : 02-2285-2507
À̸ÞÀÏ :
secretariat@icola2022.org ±³À°Á¾·ù : ³»°ú
Âü¼®¿¹»óÀοø : 800¸í
Èñ¸ÁÆòÁ¡ : 6Á¡
Áö¿ª :
¼¿ïƯº°½Ã±³À°½Ã°£ : 18 ½Ã°£ 40ºÐ
¼¼ºÎ¼ö°·á : 140,000¿ø
ºñ°í Àü¹®ÀÇ, ±³¼ö : »çÀüµî·Ï 120,000¿ø, ÇöÀåµî·Ï 140,000¿ø / ÀüÀÓÀÇ, Àü°øÀÇ,Çлý µî : »çÀüµî·Ï 60,000¿ø, ÇöÀåµî·Ï 70,000¿ø
±¸ºÐ ¿ùÀÏ °ÀÇ½Ç ½Ã°£ ±³À°Á¦¸ñ °»ç¸í(¼Ò¼Ó) Çʼö°ú¸ñ
±³À°½Ã°£ 09-17 Room 1 08:00~08:30 Lipid management : To the perfection and state of art HyoIn Choi(Sunkyunkwan University, Korea)
Åä·Ð 09-17 Room 1 08:30~08:40 Discussion ()
±³À°½Ã°£ 09-17 Room 2 08:00~08:30 Management of Poorly Controlled Patients with Diabetes Mellitus Yong-ho Lee(Yonsei University, Korea)
Åä·Ð 09-17 Room 2 08:30~08:40 Discussion ()
±³À°½Ã°£ 09-17 Room 1,2,3 09:00~09:40 New look at PCSK9 metabolism & its clinical implications Sergio Fazio(Stanford University, USA)
ÈÞ½Ä 09-17 09:40~09:45 Break ()
±³À°½Ã°£ 09-17 Room 1 09:45~10:05 What is currently best & changing in treatment of adults with Familial Hypercholesterolaemia (FH)? Won Jae Lee(Seoul National University, Korea)
±³À°½Ã°£ 09-17 Room 1 10:05~10:25 Update on familial vs mulitifactorial chylomicronemia syndrome Heung Yong Jin(Jeonbuk National University, Korea)
±³À°½Ã°£ 09-17 Room 1 10:25~10:45 Understanding role of ANGPTL3 & neighbor molecules Hun-Jun Park(The Catholic University of Korea, Korea)
Åä·Ð 09-17 Room 1 10:45~11:10 Discussion ()
±³À°½Ã°£ 09-17 Room 2 09:45~10:05 Impact of lipases on human dyslipidemia & atherosclerosis Hayato Tada(Kanazawa University, Japan)
±³À°½Ã°£ 09-17 Room 2 10:05~10:25 Screening new genes for therapeutics against dyslipidemia & atherosclerosis Alan Remaley(National Institute of Health, USA)
±³À°½Ã°£ 09-17 Room 2 10:25~10:45 Understanding strength & limitation of platforms in drug development Dong Ki Lee(OliX Pharmaceuticals, Korea)
Åä·Ð 09-17 Room 2 10:45~11:10 Discussion ()
±³À°½Ã°£ 09-17 Room 3 09:45~10:05 Challenges & perspective of drugs for Lp(a) Gisette Reyes-Soffer(Columbia University, USA)
±³À°½Ã°£ 09-17 Room 3 10:05~10:25 For whom & how much will bempedoic acid work? Raul Santos(University of São Paulo, Brazil)
±³À°½Ã°£ 09-17 Room 3 10:25~10:45 Recent trial results of new drugs targeting TG rich lipoprotein Eun Ho Choo(The Catholic University of Korea, Korea)
Åä·Ð 09-17 Room 3 10:45~11:10 Discussion ()
±³À°½Ã°£ 09-17 Room 4 09:45~10:05 Organ crosstalk under atherogenic diet Chosoon Jang(University of California Irvine, USA)
±³À°½Ã°£ 09-17 Room 4 10:05~10:25 Emerging role of epigenetic regulation by nutrients in inflammation & atherosclerosis Hyun Ju Kang(Keimyung University, Korea)
±³À°½Ã°£ 09-17 Room 4 10:25~10:45 Transition to metabolically unhealthy status & cardiometabolic risks Yongjoo Park(Chonnam National University, Korea)
Åä·Ð 09-17 Room 4 10:45~11:10 Discussion ()
ÈÞ½Ä 09-17 11:15~11:25 Coffee Break ()
±³À°½Ã°£ 09-17 Room 1,2,3 11:25~12:05 Best approach to cardio & cerebrovascular health in elderly Hidenori Arai(National Center for Geriatrics & Gerontology, Japan)
±³À°½Ã°£ 09-17 Room 1 12:05~12:35 Treatment of Dyslipidemia with Rosuvastatin and Ezetimibe Sang-Hyun Kim(Seoul National University, Korea)
Åä·Ð 09-17 Room 1 12:35~12:45 Discussion ()
±³À°½Ã°£ 09-17 Room 2 12:05~12:35 Why should we consider Rosuvastatin + Ezetimibe Fixed Dose Combination Seung-Woon Rha(Korea University, Korea)
Åä·Ð 09-17 Room 2 12:35~12:45 Discussion ()
±³À°½Ã°£ 09-17 Room 3 12:05~12:35 Key Updates in the Recent Guidelines – Identifying Patients for Evolocumab Therapy WonJae Lee(Seoul National University, Korea)
Åä·Ð 09-17 Room 3 12:35~12:45 Discussion ()
±³À°½Ã°£ 09-17 Room 4 12:05~12:35 The time for intensive LLT in very high-risk patients based on the updated Korean guideline Ho-Youn Won(Chung-Ang University, Korea)
Åä·Ð 09-17 Room 4 12:35~12:45 Discussion ()
ÈÞ½Ä 09-17 12:55~13:00 Break ()
±³À°½Ã°£ 09-17 Room 1,2,3 13:00~13:30 Up close & personal with vascular diseases: The role of precision medicine Maria Teresa Abola(University of the Philippines, Philippines)
ÈÞ½Ä 09-17 13:30~13:35 Break ()
±³À°½Ã°£ 09-17 Room 1 13:35~13:42 Evaluation of the paradoxical association between lipid levels and incident atrial fibrillation according to statin usage: a nationwide cohort study Hyojeong Ahn(Seoul National University, Korea)
±³À°½Ã°£ 09-17 Room 1 13:42~13:49 Comparison of cerebro-cardiovascular prognosis between cholesterol exposure estimate and cholesterol variability Hyung Joon Joo(Korea University, Korea)
±³À°½Ã°£ 09-17 Room 1 13:49~13:56 Early change in glucose level and risk of new-on diabetes in patients initiating statin treatment Choongki Kim(Ewha Womans University, Korea)
±³À°½Ã°£ 09-17 Room 1 13:56~14:03 Low-density lipoprotein cholesterol level, statin use and myocardial infarction risk in young adults Mee Kyoung Kim(The Catholic University of Korea, Korea)
Åä·Ð 09-17 Room 1 14:03~14:20 Q&A ()
±³À°½Ã°£ 09-17 Room 2 13:35~13:42 Ginsenoside Rh1 abolishes ROS-dependent KLF4 signaling pathway to inhibit proliferation and migration of vascular smooth muscle cells Diem Thi Ngoc Huynh(Chungnam National University, Korea)
±³À°½Ã°£ 09-17 Room 2 13:42~13:49 PCSK9 inhibitors inhibit monocyte adherence to stimulated human coronary artery endothelial cells Rahayu Zulkapli(Universiti Teknologi MARA, Malaysia)
±³À°½Ã°£ 09-17 Room 2 13:49~13:56 Lipoprotein(a) and cardiovascular and all-cause mortality in Korean adults Byung Jin Kim(Sungkyunkwan University, Korea)
±³À°½Ã°£ 09-17 Room 2 13:56~14:03 Saffron: a potential natural alternative remedy for statin intolerance Iman Nabilah Abd Rahim(Universiti Teknologi MARA, Malaysia)
Åä·Ð 09-17 Room 2 14:03~14:20 Q&A ()
ÈÞ½Ä 09-17 14:35~14:45 Coffee Break ()
±³À°½Ã°£ 09-17 Room 1 14:45~15:05 Tips for performing nationwide big cohort studies Pil-Sung Yang(Cha University, Korea)
±³À°½Ã°£ 09-17 Room 1 15:05~15:25 Advance of AI utility in past 5 years in ASCVD care: overview Jun Hwan Cho(Chung-Ang University, Kore)
±³À°½Ã°£ 09-17 Room 1 15:25~15:45 Device-based care for CV risk factors Hak Seung Lee(Medical AI, Korea)
Åä·Ð 09-17 Room 1 15:45~16:10 Discussion ()
±³À°½Ã°£ 09-17 Room 2 14:45~15:05 What's new in vascular calcification in atherosclerosis? In-Kyu Lee(Kyungpook National University, Korea)
±³À°½Ã°£ 09-17 Room 2 15:05~15:25 Celluar senescence in atherosclerosis Jae-Ryong Kim(Yeungnam University, Korea)
±³À°½Ã°£ 09-17 Room 2 15:25~15:45 Extracellular vesicles & endothelial cells Kihwan Kwon(Ewha Womans University, Korea)
Åä·Ð 09-17 Room 2 15:45~16:10 Discussion ()
±³À°½Ã°£ 09-17 Room 3 14:45~15:05 Characteristics of dyslipidemia & ASCVD of women in Korea Mi-Na Kim(Korea University, Korea)
±³À°½Ã°£ 09-17 Room 3 15:05~15:25 Sex difference in diagnosis & treatment of ASCVD: what do we need to improve in women? Ping-Yen Liu(National Cheng Kung University, Taiwan)
±³À°½Ã°£ 09-17 Room 3 15:25~15:45 Is there difference of response to lipid-lowering therapy in women? Chih-Fan Yeh(National Taiwan University, Taiwan)
Åä·Ð 09-17 Room 3 15:45~16:10 Discussion ()
±³À°½Ã°£ 09-17 Room 4 14:45~15:05 Practical approach of PCSK9 Ab use in primary & secondary prevention Young Joon Hong(Chonnam National University, Korea)
±³À°½Ã°£ 09-17 Room 4 15:05~15:25 Comparison of two drug platforms (Abs & siRNA) Richard O¡¯Brien(University of Melbourne, Australia)
±³À°½Ã°£ 09-17 Room 4 15:25~15:45 Patients who are resistant to or hypo-respond to PCSK9 inhibitors – a therapeutic challenge Edward Janus(University of Melbourne, Australia)
Åä·Ð 09-17 Room 4 15:45~16:10 Discussion ()